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Aims
To compare frovatriptan 2.5 mg plus dexketoprofen 25 or
37.5 mg (FroDex 25 and FroDex 37.5) vs. frovatriptan 2.5
mg (Frova) in the acute treatment of migraine attacks in a
post-hoc analysis of a double-blind, randomized, parallel-
group study. Patients who took the drug within 30 min
from the onset of pain (early use, EU) or after (late use,
LU) were analyzed.
Methods
314 migraineurs with or without aura treated at least
one attack with Frova, FroDex 25 or FroDex 37.5. Tradi-
tional migraine endpoints were compared across study
drugs in the 279 patients of the full analysis set accord-
ing to EU (n = 172) or LU (n = 107).
Results
Pain free (PF) at 2-hours in EU was 33% with Frova, 50%
with FroDex 25 and 51% with FroDex 37.5 (p = NS), while
in LU was 22%, 51% and 50% (p < 0.05 combinations vs.
monotherapy), respectively. PF at 4-hours was 54% for EU
and 34% for LU of Frova, 71% and 57% with FroDex 25
and 74% and 68% with FroDex 37.5 (p < 0.05 for EU and
p < 0.01 for LU vs. Frova). Sustained pain free at 24-hours
was 26% under Frova, 43% under FroDex 25 and 40%
under FroDex 37.5 (p = NS) in EU, while it was 19%
under Frova, 43% under FroDex 25 and 45% under Fro-
Dex 37.5 (p < 0.05 FroDex 25 and FroDex 37.5 vs. Frova)
in LU. Risk of relapse at 48-hours was similar (p = NS)
among study groups (Frova: 25%, FroDex 25: 21%, and
FroDex 37.5: 37%) for both EU and LU (14%, 42% and
32%).
Conclusions
FroDex was found to be more effective than Frova taken
either early or late.
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